# Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

> **NCT01147744** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 700 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Propionate 100mcg via ACCUHALER/DISKUS
- **DRUG:** GSK2190915 100mg
- **DRUG:** GSK2190915 10mg
- **DRUG:** GSK2190915 300mg
- **DRUG:** GSK2190915 30mg
- **DRUG:** Montelukast 10mg
- **DRUG:** Placebo GSK2190915 one tablet
- **DRUG:** Placebo montelukast
- **DRUG:** Placebo fluticasone propionate via ACCUHALER/DISKUS
- **DRUG:** Placebo GSK2190915 two tablets

## Key facts

- **NCT ID:** NCT01147744
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-28
- **Primary completion:** 2011-10-06
- **Final completion:** 2011-10-06
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2017-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147744, "Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01147744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*